Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ASH 2022
Research
Takeda, Poseida see promising data for hemophilia A gene therapy
Takeda's $3.6 billion deal with Poseida Therapeutics is paying off with promising preclinical data on the companies’ hemophilia A therapy P-FVIII-101.
Helen Floersh
Dec 14, 2022 3:15pm
Novartis stays the course on cell therapy bet after phase 1 data
Dec 13, 2022 10:00am
Novartis touts new budding disease med as it battles AstraZeneca
Dec 13, 2022 10:00am
ASH: Should existing BTKs worry about Lilly's newcomer?
Dec 12, 2022 5:30pm
Janssen peels back layer of data on its new myeloma bispecifc
Dec 12, 2022 10:10am
ASH: BCMA battle heats up as Gracell dazzles with 100% ORR in MM
Dec 12, 2022 5:55am
